Biotech News

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Oculis (OCS)Oculis2026-10-01 06:00 ESTCompany update

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG

Oculis

Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...

Recent company news

OCSOculis2026-10-01 06:00 EST

Stock data

Close: 8.73 USD
Market cap: 742.17M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Related news

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

Oculis Reports Q1 2026 Financial Results and Provides Company Update

Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis

CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis

Oculis

Recent company news

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Oculis Announces Resignation of Lionel Carnot from Board of Directors

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Stock data